Search research articles
Contact Us
Filters
Showing results (1-10 of 108) with videos related to
Page
of 11
Sort By:
Lancet (London, England)
|
July 26, 2005
High-dose chemotherapy and allogeneic immunotherapy
Richard Childs, Ramaprasad Srinivasan
The Lancet. Oncology
|
July 3, 2025
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors - Authors' reply
Ramaprasad Srinivasan, Eric Jonasch
Current Oncology Reports
|
June 22, 2016
Therapeutic Strategies for Hereditary Kidney Cancer
Abhinav Sidana, Ramaprasad Srinivasan
Nature Clinical Practice. Urology
|
February 9, 2007
Antiangiogenic therapy in renal cell carcinoma: from concept to reality
Ramaprasad Srinivasan, W Marston Linehan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2004
Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer
Ramaprasad Srinivasan, W Marston Linehan
Urologic Oncology
|
October 22, 2011
Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events
Eric A Singer, Ramaprasad Srinivasan
Nature Reviews. Clinical Oncology
|
October 17, 2013
Targeted therapies: treating advanced kidney cancer-miles to go before we sleep
W Marston Linehan, Ramaprasad Srinivasan
Nature Reviews. Urology
|
January 17, 2018
Kidney cancer in 2017: Challenging and refining treatment paradigms
Mark W Ball, Ramaprasad Srinivasan
The Journal of Urology
|
November 16, 2010
Editorial comment
Eric A Singer, Ramaprasad Srinivasan, Gennady Bratslavsky
European Urology
|
September 28, 2025
Reply to Changhong Xu, Hanxue Zheng, Yun Deng, and Li Yang's Letter to the Editor re: W. Marston Linehan, Cathy Anne Pinto, Yangang Liu, et al. Longitudinal Evaluation of Clear-cell Renal cell Carcinoma in von Hippel-Lindau Disease. Eur Urol 2025:88:56-63
W Marston Linehan, Mark Ball, Ramaprasad Srinivasan
Page
of 11
Search research articles
Search
Showing results (1-10 of 108) with videos related to
Sort By:
Page
of 11
Lancet (London, England)
|
July 26, 2005
High-dose chemotherapy and allogeneic immunotherapy
Richard Childs, Ramaprasad Srinivasan
The Lancet. Oncology
|
July 3, 2025
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors - Authors' reply
Ramaprasad Srinivasan, Eric Jonasch
Current Oncology Reports
|
June 22, 2016
Therapeutic Strategies for Hereditary Kidney Cancer
Abhinav Sidana, Ramaprasad Srinivasan
Nature Clinical Practice. Urology
|
February 9, 2007
Antiangiogenic therapy in renal cell carcinoma: from concept to reality
Ramaprasad Srinivasan, W Marston Linehan
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 2, 2004
Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer
Ramaprasad Srinivasan, W Marston Linehan
Urologic Oncology
|
October 22, 2011
Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events
Eric A Singer, Ramaprasad Srinivasan
Nature Reviews. Clinical Oncology
|
October 17, 2013
Targeted therapies: treating advanced kidney cancer-miles to go before we sleep
W Marston Linehan, Ramaprasad Srinivasan
Nature Reviews. Urology
|
January 17, 2018
Kidney cancer in 2017: Challenging and refining treatment paradigms
Mark W Ball, Ramaprasad Srinivasan
The Journal of Urology
|
November 16, 2010
Editorial comment
Eric A Singer, Ramaprasad Srinivasan, Gennady Bratslavsky
European Urology
|
September 28, 2025
Reply to Changhong Xu, Hanxue Zheng, Yun Deng, and Li Yang's Letter to the Editor re: W. Marston Linehan, Cathy Anne Pinto, Yangang Liu, et al. Longitudinal Evaluation of Clear-cell Renal cell Carcinoma in von Hippel-Lindau Disease. Eur Urol 2025:88:56-63
W Marston Linehan, Mark Ball, Ramaprasad Srinivasan
Page
of 11